CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below.
All CIRM Grants
Search Filters »
Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
Children’s Hospital of Los Angeles |
Dr. Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$850,769 |
University of California, San Francisco |
Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$2,756,536 |
Buck Institute for Age Research |
Dr. Xianmin Zeng |
Early Translational II |
Banking transplant ready dopaminergic neurons using a scalable process |
$4,983,013 |
iPierian, Inc. |
Dr. John Dimos |
Early Translational II |
New Drug Discovery for SMA using Patient-derived Induced Pluripotent Stem Cells |
$2,410,000 |
University of California, Los Angeles |
Prof. Bruno Peault |
Early Translational II |
Harnessing native fat-residing stem cells for bone regeneration |
$5,359,076 |
Scripps Research Institute |
Peter G. Schultz |
Early Translational II |
Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis |
$6,047,249 |
University of California, San Diego |
Professor Alysson R Muotri |
Early Translational II |
Developing a drug-screening system for Autism Spectrum Disorders using human neurons |
$1,376,198 |
University of California, Irvine |
Dr. Leslie M Thompson |
Early Translational II |
A hESc-based Development Candidate for Huntington’s Disease |
$3,955,038 |
University of California, San Diego |
Catriona Jamieson |
Early Translational II |
Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy |
$3,103,041 |
Gladstone Institutes, J. David |
Dr. Todd C. McDevitt |
Research Leadership |
Engineering microscale tissue constructs from human pluripotent stem cells |
$5,849,100 |
University of California, Los Angeles |
Dr. John P Chute |
Research Leadership |
Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors |
$4,645,297 |
University of California, Berkeley |
Dr. Xavier Darzacq |
Research Leadership |
Single Molecule Biophysics and Biology of Cellular Identity |
$4,175,924 |
University of California, San Francisco |
Redacted |
Research Leadership |
Recapitulating development of the musculoskeletal axis in vitro with pluripotent cells |
$0 |
University of California, San Diego |
Dr. Eric T. Ahrens |
Research Leadership |
Molecular Imaging for Stem Cell Science and Clinical Application |
$5,680,474 |
University of California, Santa Cruz |
Professor Richard Gregory |
Research Leadership |
MicroRNA Regulation in Stem Cells, Development, and Disease |
$0 |
Stanford University |
Professor Hiromitsu Nakauchi |
Research Leadership |
Generation of functional cells and organs from iPSCs |
$5,426,135 |
Gladstone Institutes, J. David |
Dr. Kevin Kit Parker PhD |
Research Leadership |
Engineering Cardiac Tissue for Regeneration and Drug Development |
$0 |
Cedars-Sinai Medical Center |
Dr. Barry R Stripp |
Research Leadership |
Epithelial progenitors and the stromal niche as therapeutic targets in lung disease |
$4,841,830 |
Parkinson’s Institute |
Dennis Steindler |
Research Leadership |
Stem Cell Pathologies in Parkinson’s disease as a key to Regenerative Strategies |
$0 |
University of Southern California |
Dr. Andrew McMahon |
Research Leadership |
Repair and regeneration of the nephron |
$5,672,206 |
University of California, Berkeley |
Dr. Zhigang He |
Research Leadership |
Developing a regeneration-based functional restoration treatment for spinal cord injury |
$0 |
University of California, Santa Barbara |
Professor Peter J Coffey |
Research Leadership |
Development of Cellular Therapies for Retinal Disease |
$4,690,963 |
Sanford Burnham Prebys Medical Discovery Institute |
Dr. Robert J Wechsler-Reya |
Research Leadership |
The role of neural stem cells in cerebellar development, regeneration and tumorigenesis |
$5,226,049 |
Mohammad Pashmforoush |
Dr. Mohammad Pashmforoush |
New Faculty I |
Medical School Loan Repayment Program |
$27,949 |
Salk Institute for Biological Studies |
Dr. Dana Leanne Jones |
New Faculty I |
Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity |
$2,134,100 |
University of California, Los Angeles |
Dr. Dana Leanne Jones |
New Faculty I |
Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity |
$382,773 |
University of California, Los Angeles |
Dr. Siavash Kurdistani |
New Faculty I |
Epigenetics in cancer stem cell initiation and clinical outcome prediction |
$3,063,450 |
University of California, Santa Cruz |
Dr. Camilla Forsberg |
New Faculty I |
Mechanisms of Stem Cell Fate Decisions |
$2,201,759 |
University of Southern California |
Dr. Mohammad Pashmforoush |
New Faculty I |
Transcriptional Regulation of Cardiac Pacemaker Cell Progenitors |
$2,816,578 |
University of California, Berkeley |
Dr. Irina M. Conboy |
New Faculty I |
Identification of hESC-mediated molecular mechanism that positively regulates the regenerative capacity of post-natal tissues |
$2,246,020 |
University of California, Santa Cruz |
Dr. Bin Chen |
New Faculty I |
Molecular mechanisms of neural stem cell differentiation in the developing brain |
$2,147,592 |
University of California, Los Angeles |
Dr. Kathrin Plath Dr. |
New Faculty I |
In vitro reprogramming of mouse and human somatic cells to an embryonic state |
$2,229,427 |
The Regents of the University of California on behalf of its Riverside Campus |
Dr. Douglas Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer’s Disease |
$621,639 |
Western University of Health Sciences |
Dr. Douglas W Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer’s Disease |
$1,401,642 |
University of California, Davis |
Dr. Chong-Xian Pan |
New Faculty I |
Combinatorial Chemistry Approaches to Develop LIgands against Leukemia Stem Cells |
$2,386,409 |
University of California, Los Angeles |
Dr. Hanna Mikkola |
New Faculty I |
Mechanisms of Hematopoietic stem cell Specification and Self-Renewal |
$2,286,900 |
City of Hope, Beckman Research Institute |
Dr. Tiziano Barberi |
New Faculty I |
Skeletal muscle development from hESC and its in vivo applications in animal models of muscular dystrophy |
$131,840 |
Scripps Research Institute |
Dr. Kristin K Baldwin Dr. |
New Faculty I |
Generating pluripotent cell lines from neurons. |
$2,786,560 |
Salk Institute for Biological Studies |
Dr. Lei Wang |
New Faculty I |
Genetic Encoding Novel Amino Acids in Embryonic Stem Cells for Molecular Understanding of Differentiation to Dopamine Neurons |
$2,587,742 |
Stanford University |
Dr. Anne Brunet |
New Faculty I |
Molecular mechanisms involved in adult neural stem cell maintenance |
$2,348,435 |
University of California, Merced |
Dr Jennifer O Manilay |
New Faculty I |
Enhancing Survival of Embryonic Stem Cell-Derived Grafts by Induction of Immunological Tolerance |
$1,576,389 |
University of California, Irvine |
Dr. Andrew Putnam |
New Faculty I |
A Novel Engineered Niche to Explore the Vasculogenic Potential of Embryonic Stem Cells |
$395,764 |
Stanford University |
Dr. Joanna Wysocka PhD |
New Faculty I |
Trithorax and Polycomb methyltransferase complexes in cell fate determination. |
$2,373,903 |
University of California, San Diego |
Dr. David Traver |
New Faculty I |
Genetic dissection of mesodermal commitment to the hematopoietic fates. |
$2,150,620 |
University of Southern California |
Dr. Songtao Shi |
New Faculty I |
Oral and Craniofacial Reconstruction Using Mesenchymal Stem Cells |
$3,242,651 |
Scripps Research Institute |
Dr. Sheng Ding Dr. |
New Faculty I |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,393,876 |
Gladstone Institutes, J. David |
Sheng Ding PhD |
New Faculty I |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,320,101 |
Stanford University |
Karl Deisseroth |
New Faculty I |
Bioengineering technology for fast optical control of differentiation and function in stem cells and stem cell progeny |
$2,424,209 |
Stanford University |
Dr. Howard Y. Chang |
New Faculty I |
Noncoding RNAs in Cell Fate Determination |
$2,985,894 |
BioTime, Inc. |
Dr. Michael D West Ph.D. |
Early Translational I |
Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines |
$4,721,706 |